We are live on ! Find out more

930 hedge funds and large institutions have $49.5B invested in DexCom in 2021 Q4 according to their latest regulatory filings, with 197 funds opening new positions, 343 increasing their positions, 271 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

279% more first-time investments, than exits

New positions opened: 197 | Existing positions closed: 52

27% more repeat investments, than reductions

Existing positions increased: 343 | Existing positions reduced: 271

17% more funds holding

Funds holding: 795930 (+135)

3% less capital invested

Capital invested by funds: $51.1B → $49.5B (-$1.57B)

9% less call options, than puts

Call options by funds: $987M | Put options by funds: $1.09B

6.21% less ownership

Funds ownership: 387.53%381.32% (-6.2%)

13% less funds holding in top 10

Funds holding in top 10: 1513 (-2)

Holders
930
Holders Change
+135
Holders Change %
+16.98%
% of All Funds
14.31%
Holding in Top 10
13
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-13.33%
% of All Funds
0.2%
New
197
Increased
343
Reduced
271
Closed
52
Calls
$987M
Puts
$1.09B
Net Calls
-$99.4M
Net Calls Change
-$269M

DXCM Hedge Fund Activity: Q4 2021 in Review

930 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q4 2021, worth a combined $49.5B — down 3.1% from $51.1B a quarter earlier.

Buyers outnumbered sellers: 197 funds opened new DXCM positions and 52 closed out — a net gain of 145 holders — while 343 added to existing stakes and 271 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $486M. The largest seller was Lone Pine Capital, exiting entirely with an estimated $788M sold.

  • 930 institutional investors held DexCom (DXCM) as of Q4 2021, up from 795 in Q3 2021.
  • Funds reported $49.5B of DexCom stock for Q4 2021, down 3.1% quarter-over-quarter.
  • 197 funds opened new DexCom positions in Q4 2021 and 52 closed out, a net change of +145 holders.
  • The largest DexCom buyer in Q4 2021 was Capital Research Global Investors, an estimated $486M added.
  • The largest DexCom seller in Q4 2021 was Lone Pine Capital, an estimated $788M sold.

Based on aggregated 13F filings for Q4 2021.